RxDoctor Payments Data

Larry Cohen, MD

Cardiovascular Disease · Edison, NJNPI 1295731305

Payments from drug & device makers

$12,293in general payments, 2019–2025

Across 178 payments — averaging $69.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$8K
  • Boston Scientific$2K
  • Cvrx, Inc.$517
  • Novartis$314
  • Merck$302
  • Amgen$256
  • plus $1K from 18 others

What the payments were for

  • Speaking & faculty fees$6,42552%
  • Travel & lodging$2,40720%
  • Food & beverage$3,42528%
  • Education$360%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,293 in reported general payments places this provider in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$380,551
Medicare patients
684
Services billed
3,209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban251$301,716
EliquisApixaban188$197,067
JardianceEmpagliflozin132$164,742
EntrestoSacubitril/Valsartan105$134,997
FarxigaDapagliflozin Propanediol82$75,100
MounjaroTirzepatide51$69,393
JanuviaSitagliptin Phosphate39$44,604
Repatha SureclickEvolocumab25$38,184
JanumetSitagliptin Phos/Metformin Hcl37$32,497
BrilintaTicagrelor33$29,256
OzempicSemaglutide13$20,721
WegovySemaglutide13$16,271
Nebivolol Hcl178$13,837
Breo ElliptaFluticasone/Vilanterol21$11,932
Repatha PushtronexEvolocumab16$11,742

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$7,559$301,716251 claims
PfizerEliquis$160$197,067188 claims
Boehringer IngelheimJardiance$88$164,742132 claims
NovartisEntresto$314$134,997105 claims
AstraZenecaFarxiga, Brilinta$202$104,356115 claims
MerckJanuvia, Janumet$302$77,10176 claims
Lilly USA, LLCMounjaro$40$69,39351 claims
Novo NordiskOzempic, Wegovy$148$36,99226 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$26$11,13424 claims
AbbVieSynthroid$124$5,53283 claims
Daiichi Sankyo Inc.Tribenzor$15$5,42312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Edison

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →